2024-06-04 13:31:03 ET
Merck & Co., Inc. (MRK)
Investor Event at ASCO 2024
June 3, 2024 07:00 PM ET
Company Participants
Peter Dannenbaum - Senior Vice President, Investor Relations
Dean Li - President of Merck Research Labs
Eliav Barr - Chief Medical Officer & Head of Global Clinical Development
Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development
Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health
Joanne Monahan - Senior Vice President, US Oncology
Conference Call Participants
Carter Gould - Barclays
Chris Schott - JPMorgan
Evan Seigerman - BMO Capital Markets
Akash Tewari - Jefferies
Steve Scala - TD Cowen
Chris Shibutani - Goldman Sachs
Trung Huynh - UBS
Mohit Bansal - Wells Fargo
Dan Ziment - Morgan Stanley
Daina Graybosch - Leerink Partners
Presentation
Operator
Thank you for standing by. Welcome to the Merck & Co., Inc. Investor Event at the American Society of Clinical Oncology Annual Meeting. [Operator Instructions] This call is being recorded. If you have any objections, you may disconnect at this time.
I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations.
Peter Dannenbaum
Thank you, Julie. Good evening, everyone. Welcome to Merck's investor event here at the American Society of Clinical Oncology Annual Meeting, and thank you to all of you that are in the room here with us tonight and to all of you tuning in via the webcast. Thank you, thanks for your attention and the effort you made to get here.
We're excited to have this opportunity to speak to you about Merck's oncology program. During today's call, a slide presentation will accompany our speakers' prepared remarks. It's been posted to the Investor Relations section of Merck's website.
And before we get started, we'd like to remind you that some of the statements that we make during today's call may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of Merck's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Please reference this slide in our presentation and our 2023 10-K, which identifies certain risk factors and cautionary statements.
It's now my pleasure to introduce Dr. Dean Li, President of Merck Research Labs, who will make a few opening remarks and outline our agenda and speaker lineup. Dean?
Dean Li
Thank you. Thank you very much for all of you for being here, and thank you, Peter. It's a pleasure to be here with all of you in the room and also all of you who are here virtually as well....
Read the full article on Seeking Alpha
For further details see:
Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript)